TY - JOUR
T1 - The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS)
T2 - Trophoblast invasiveness and APS animal model
AU - Blank, Miri
AU - Anafi, Liat
AU - Zandman-Goddard, Gisele
AU - Krause, Ilan
AU - Goldman, Shlomit
AU - Shalev, Eliezer
AU - Cervera, Ricard
AU - Font, Josep
AU - Fridkin, Mati
AU - Thiesen, Hans Jurgen
AU - Shoenfeld, Yehuda
N1 - Funding Information:
This work was supported by AUTOROME European Community grant no. LSHM-CT-2004-005264.
PY - 2007/7
Y1 - 2007/7
N2 - Objectives: Administration of intravenous Ig (IVIG) is a recognized, safe and efficient mode of immunomodulatory therapy for many autoimmune diseases. Anti-idiotypic antibody binding to pathogenic autoantibodies and hence inhibition of binding to the corresponding antigen is one postulated mechanism of the beneficial effect of IVIG. The aim of this study was to fractionate the anti-beta-2-glycoprotein-I (β2GPI) anti-idiotypic antibodies from a commercial IVIG preparation and use it as a treatment in an experimental antiphospholipid syndrome (APS) mouse model. Methods: Anti-β2GPI polyclonal antibodies were purified on a β2GPI column. The purified antibodies were bound to CN-Br-activated sepharose and employed for purification of IVIG-anti-anti-β2GPI (anti-idiotypic antibodies), defined as specific intravenous Ig (sIVIG). The idiotype specificities were confirmed by competition assays. The effect of sIVIG in vitro was tested in a trophoblast and choriocarcinoma matrigel/invasion assay (i.e. proliferation and metalloproteinase (MMP)2/MMP9 expression) and in vivo in a fetal loss model of APS. Results: Anti-β2GPI antibodies inhibited human trophoblast cell invasion in vitro. The function was attributed to the Fab portion of the anti-β2GPI Igs, since β2GPI-related synthetic peptides specific for the Fab part of the anti-β2GPI antibodies neutralized its activity. APS sIVIG fraction reduce human trophoblast invasion in vitro by 560 times more than the whole IVIG compound and improved the MMP2 and MMP9 production by trophoblast cells. sIVIG improved significantly (200 times more) the pregnancy outcome in BALB/c mice passively infused with anti-β2GPI antibodies, in comparison to treatment with IVIG (P < 0.02). Conclusions: Based on the current results, we propose that APS sIVIG may be considered as potential specific therapeutic safe compound for developing a treatment for APS patient's early fetal loss.
AB - Objectives: Administration of intravenous Ig (IVIG) is a recognized, safe and efficient mode of immunomodulatory therapy for many autoimmune diseases. Anti-idiotypic antibody binding to pathogenic autoantibodies and hence inhibition of binding to the corresponding antigen is one postulated mechanism of the beneficial effect of IVIG. The aim of this study was to fractionate the anti-beta-2-glycoprotein-I (β2GPI) anti-idiotypic antibodies from a commercial IVIG preparation and use it as a treatment in an experimental antiphospholipid syndrome (APS) mouse model. Methods: Anti-β2GPI polyclonal antibodies were purified on a β2GPI column. The purified antibodies were bound to CN-Br-activated sepharose and employed for purification of IVIG-anti-anti-β2GPI (anti-idiotypic antibodies), defined as specific intravenous Ig (sIVIG). The idiotype specificities were confirmed by competition assays. The effect of sIVIG in vitro was tested in a trophoblast and choriocarcinoma matrigel/invasion assay (i.e. proliferation and metalloproteinase (MMP)2/MMP9 expression) and in vivo in a fetal loss model of APS. Results: Anti-β2GPI antibodies inhibited human trophoblast cell invasion in vitro. The function was attributed to the Fab portion of the anti-β2GPI Igs, since β2GPI-related synthetic peptides specific for the Fab part of the anti-β2GPI antibodies neutralized its activity. APS sIVIG fraction reduce human trophoblast invasion in vitro by 560 times more than the whole IVIG compound and improved the MMP2 and MMP9 production by trophoblast cells. sIVIG improved significantly (200 times more) the pregnancy outcome in BALB/c mice passively infused with anti-β2GPI antibodies, in comparison to treatment with IVIG (P < 0.02). Conclusions: Based on the current results, we propose that APS sIVIG may be considered as potential specific therapeutic safe compound for developing a treatment for APS patient's early fetal loss.
KW - Antiphospholipid syndrome
KW - Autoantibodies
KW - Beta-2-glycoprotein-I
KW - Experimental model
KW - IVIG
UR - http://www.scopus.com/inward/record.url?scp=34547771658&partnerID=8YFLogxK
U2 - 10.1093/intimm/dxm052
DO - 10.1093/intimm/dxm052
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:34547771658
SN - 0953-8178
VL - 19
SP - 857
EP - 865
JO - International Immunology
JF - International Immunology
IS - 7
ER -
